Persistent Asset Partners’s Parabilis Medicines Inc PBLS Stock Holding History

Persistent Asset Partners’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Buy	+4,130	New	+$114K	0.03%	276

Other funds holding PBLS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Persistent Asset Partners's PBLS Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 4,130 shares worth $113K. The stake represents 0.03% of the portfolio and ranks #276 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Persistent Asset Partners held 4,130 shares of Parabilis Medicines Inc worth $113K as of Q2 2026.
Parabilis Medicines Inc was a new Persistent Asset Partners position in Q2 2026.
Parabilis Medicines Inc made up 0.03% of Persistent Asset Partners's portfolio in Q2 2026, its #276 holding.
79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.